AU2002220276A1 - Spiro(isobenzofuran-1,4'-piperidin)-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines - Google Patents

Spiro(isobenzofuran-1,4'-piperidin)-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines

Info

Publication number
AU2002220276A1
AU2002220276A1 AU2002220276A AU2027602A AU2002220276A1 AU 2002220276 A1 AU2002220276 A1 AU 2002220276A1 AU 2002220276 A AU2002220276 A AU 2002220276A AU 2027602 A AU2027602 A AU 2027602A AU 2002220276 A1 AU2002220276 A1 AU 2002220276A1
Authority
AU
Australia
Prior art keywords
disorders
spiroisobenzofuran
isobenzofuran
piperidines
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220276A
Other languages
English (en)
Inventor
Rajagopal Bakthavatchalam
Charles A Blum
Harry L. Brielmann Jr.
James William Darrow
Stephane De Lombaert
Richard Louis Elliott
Marlys Hammond
Alan Hutchison
Jennifer Tran
Xiaozhang Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of AU2002220276A1 publication Critical patent/AU2002220276A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002220276A 2000-12-12 2001-12-11 Spiro(isobenzofuran-1,4'-piperidin)-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines Abandoned AU2002220276A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25499000P 2000-12-12 2000-12-12
US60/254,990 2000-12-12
PCT/US2001/047863 WO2002048152A2 (en) 2000-12-12 2001-12-11 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines

Publications (1)

Publication Number Publication Date
AU2002220276A1 true AU2002220276A1 (en) 2002-06-24

Family

ID=22966369

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220276A Abandoned AU2002220276A1 (en) 2000-12-12 2001-12-11 Spiro(isobenzofuran-1,4'-piperidin)-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines

Country Status (10)

Country Link
US (4) US6566367B2 (enExample)
EP (1) EP1347982B1 (enExample)
JP (1) JP2004520299A (enExample)
AT (1) ATE310004T1 (enExample)
AU (1) AU2002220276A1 (enExample)
BR (1) BR0116113A (enExample)
DE (1) DE60115092T2 (enExample)
ES (1) ES2249384T3 (enExample)
MX (1) MXPA03004245A (enExample)
WO (1) WO2002048152A2 (enExample)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
WO2000027845A1 (en) 1998-11-10 2000-05-18 Merck & Co., Inc. Spiro-indolines as y5 receptor antagonists
KR20020047198A (ko) * 1999-09-30 2002-06-21 해피 페너 ; 해리 에이치. 페너 2세 특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진
OA12050A (en) 1999-09-30 2006-05-02 Neurogen Corp Certain alkylene diamine-substituted heterocycles.
AU2001239731A1 (en) * 2000-01-28 2001-08-07 Neurogen Corporation Chimeric neuropeptide y receptors
EP1347982B1 (en) * 2000-12-12 2005-11-16 Neurogen Corporation Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
WO2002094825A1 (en) * 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Novel spiropiperidine derivative
US7205417B2 (en) * 2001-08-07 2007-04-17 Banyu Pharmaceutical Co., Ltd. Spiro compounds
CA2403307A1 (en) 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
AUPR975601A0 (en) * 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
CA2484209C (en) * 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7105526B2 (en) * 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JP4496722B2 (ja) * 2002-06-28 2010-07-07 萬有製薬株式会社 新規ベンズイミダゾール誘導体
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
EP1407774A1 (en) * 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
EP1398032A1 (en) * 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
EP1567487A4 (en) * 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
ATE433971T1 (de) 2002-11-29 2009-07-15 Banyu Pharma Co Ltd Neue azolderivate
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
MXPA05009245A (es) 2003-03-11 2005-10-19 Pfizer Prod Inc Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf).
WO2005005395A2 (en) 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
JP4765627B2 (ja) 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体
WO2005030210A1 (en) * 2003-09-26 2005-04-07 Pfizer Products Inc. Treatment of neurological disorders related to rapid eye movement (rem) sleep disturbances with npy y5 receptor antagonists
MXPA06003380A (es) * 2003-09-26 2006-06-08 Pfizer Prod Inc Uso de antagonista del receptor npy y5 para el tratamiento de trastornos del ritmo circadiano.
US7256208B2 (en) * 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
WO2005056036A2 (en) * 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EA010888B1 (ru) 2004-05-25 2008-12-30 Пфайзер Продактс, Инк. Тетраазабензо[е]азуленовые производные и их аналоги
KR20070046929A (ko) * 2004-08-19 2007-05-03 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체 조절제
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
RU2007124373A (ru) * 2004-11-29 2009-01-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецептеров
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
DE102005012874A1 (de) * 2005-03-19 2006-09-21 Sanofi-Aventis Deutschland Gmbh Amid substituierte 8-N-Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
US8211919B2 (en) * 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
KR20080048502A (ko) * 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
JP2009521483A (ja) * 2005-12-22 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
EP1987034B1 (en) * 2006-02-22 2011-07-20 Vertex Pharmceuticals Incorporated Spiro condensed piperidines as modulators of muscarinic receptors
AU2007221214A1 (en) * 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP1847542A1 (en) * 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
CN101500565A (zh) * 2006-06-29 2009-08-05 弗特克斯药品有限公司 毒蕈碱性受体的调节剂
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
AU2007284548A1 (en) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP2051715A2 (en) 2006-08-18 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
EP2064187A2 (en) * 2006-08-25 2009-06-03 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008047544A1 (en) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US7981893B2 (en) * 2006-10-19 2011-07-19 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
CN101563323B (zh) * 2006-12-22 2012-07-04 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
FR2910473B1 (fr) * 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US7973162B2 (en) * 2007-10-03 2011-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
WO2009070584A1 (en) * 2007-11-30 2009-06-04 Wyeth Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
WO2009108332A1 (en) * 2008-02-27 2009-09-03 Vitae Pharmaceuticals, Inc. INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EP2350010B1 (en) 2008-10-30 2014-03-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010138833A1 (en) 2009-05-29 2010-12-02 Wyeth SUBSTITUTED IMIDAZO[1,5-a]QUINOXALINES AS INHIBITORS OF PHOSPHODIESTERASE 10
NZ618135A (en) 2009-10-26 2015-05-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8680098B2 (en) 2010-03-05 2014-03-25 Janssen Pharmaceutica, Nv Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
CA2799708A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
CA2828343A1 (en) 2011-03-04 2012-09-13 The Scripps Research Institute Edn3-like peptides and uses thereof
KR101978537B1 (ko) 2011-10-19 2019-05-14 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9403829B2 (en) 2011-12-02 2016-08-02 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use
JP6114317B2 (ja) 2012-02-24 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
MX2015009209A (es) 2013-01-16 2016-03-17 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CA2908353C (en) 2013-04-17 2021-11-02 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EA030726B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
AU2014254059B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
HK1223286A1 (zh) 2013-05-29 2017-07-28 西格诺药品有限公司 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
CN104387367A (zh) * 2014-11-02 2015-03-04 湖南华腾制药有限公司 一种2位取代苯并咪唑衍生物的制备方法
EP3480198B1 (en) 2016-06-30 2021-05-05 Riken Novel compound or pharmaceutically acceptable salt thereof
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
CN116462666B (zh) * 2017-01-10 2025-07-15 瑞士苏黎世联邦理工学院 细胞保护性化合物及其用途
ES2959860T3 (es) 2017-06-22 2024-02-28 Celgene Corp Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B
JP7369968B2 (ja) * 2017-12-27 2023-10-27 公益財団法人がん研究会 抗がん剤
CA3105174A1 (en) * 2018-06-27 2020-01-02 Reborna Biosciences, Inc. Prophylactic or therapeutic agent for spinal muscular atrophy
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
WO2020163689A1 (en) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors
TW202045476A (zh) 2019-02-13 2020-12-16 美商默沙東藥廠 5-烷基吡咯啶食慾素受體促效劑
EP3923933A4 (en) 2019-02-13 2022-08-17 Merck Sharp & Dohme Corp. PYRROLIDINOREXINE RECEPTOR AGONISTS
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
EP3772513A1 (en) * 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Shp2 inhibitors
MX2023001840A (es) 2020-08-18 2023-03-13 Merck Sharp & Dohme Llc Agonistas de bicicloheptano pirrolidina de los receptores de orexina.
MX2024000271A (es) * 2021-07-09 2024-01-31 Kanaph Therapeutics Inc Inhibidor de shp2 y uso del mismo.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55143980A (en) * 1979-04-27 1980-11-10 Dai Ichi Seiyaku Co Ltd Anti-allergic preparation
WO1995028389A1 (en) * 1994-04-15 1995-10-26 Yamanouchi Pharmaceutical Co., Ltd. Spiro compound and medicinal composition thereof
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
WO2000027845A1 (en) * 1998-11-10 2000-05-18 Merck & Co., Inc. Spiro-indolines as y5 receptor antagonists
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
OA12050A (en) 1999-09-30 2006-05-02 Neurogen Corp Certain alkylene diamine-substituted heterocycles.
KR20020047198A (ko) 1999-09-30 2002-06-21 해피 페너 ; 해리 에이치. 페너 2세 특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진
AU2001239731A1 (en) 2000-01-28 2001-08-07 Neurogen Corporation Chimeric neuropeptide y receptors
WO2001095856A2 (en) 2000-06-15 2001-12-20 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
EP1347982B1 (en) * 2000-12-12 2005-11-16 Neurogen Corporation Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
CA2403307A1 (en) 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives

Also Published As

Publication number Publication date
MXPA03004245A (es) 2003-09-22
US20040072847A1 (en) 2004-04-15
DE60115092D1 (de) 2005-12-22
US20030036652A1 (en) 2003-02-20
WO2002048152A2 (en) 2002-06-20
US6566367B2 (en) 2003-05-20
US6943199B2 (en) 2005-09-13
US20060040964A1 (en) 2006-02-23
ES2249384T3 (es) 2006-04-01
ATE310004T1 (de) 2005-12-15
EP1347982B1 (en) 2005-11-16
US20050033048A1 (en) 2005-02-10
BR0116113A (pt) 2004-08-03
JP2004520299A (ja) 2004-07-08
EP1347982A2 (en) 2003-10-01
DE60115092T2 (de) 2006-03-30
WO2002048152A3 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
MXPA03004245A (es) Espiro[isobenzofuran-1,4'piperidin]-3-onas y 3h-espiroisobenzofuran-1,4'-piperidinas.
WO2002094799A3 (en) Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
WO2006044174A3 (en) Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
EP1967191B8 (en) Controlled/modified release oral methylphenidate formulations
WO2006049941A3 (en) Diaryl ureas as cb1 antagonists
WO2003060475A3 (en) Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
WO2005042498A3 (en) 4-amino (aza) quinoline derivatives as capsaicin receptor agonists
WO2004056774A3 (en) Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
NZ329627A (en) 8-Heterocyclically substituted 1,3,8-triaza-spiro[4.5]decan-4-ones
AP2000001929A0 (en) Substituted indolealkanoic acids.
NZ593444A (en) 4-[(2-N,N-diethylaminocarbonyl)pyrid-5-yl]-spiro[1,2-dihydronaphthalene-2,4'-piperidine] and methods of its use
WO2005110982A3 (en) Substituted 1-benzyl-4-substituted piperazine analogues
WO2005007652A3 (en) Substituted quinolin-4-ylamine analogues
WO2006052542A3 (en) Arylalkyl ureas as cb1 antagonists
WO2006009789A3 (en) Aryl-substituted piperazine derivatives
MX339420B (es) Compuestos para la modulacion de la actividad de ppar gamma.
MXPA02010431A (es) Derivados substituidos de 2-ciclohexil-4-fenil-1h-imidazol.
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
MXPA03008681A (es) (oxo-pirazol[1,5]pirimidin-2-il)alquil-carboxamidas.
WO2004041809A3 (en) Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands
MY140697A (en) Deltamethrin-containing water-dispersible granular material
WO2005086968A3 (en) Substituted 5,12-diaza-benzoanthracene analogues
EP1935885A3 (en) Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues.
AU2003237881A1 (en) Substituted ring-fused imidazole derivates: gabaa receptor ligands
WO2005009982A3 (en) Aryl-substituted benzo[d]isothiazol-3-ylamine analogues as capsaicin receptor modulators